Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
June 04 2008 - 4:00PM
PR Newswire (US)
SEATTLE, June 4 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals
Inc. (NASDAQ:TRBN) today announced that Dr. Kendall Mohler,
co-founder and senior vice president of research and development,
is scheduled to present at the 7th Annual Needham & Company
Biotechnology & Medical Technology Conference on June 12 at 10
a.m. EDT. This conference will be held at the New York Palace Hotel
in New York City. The presentation will be available via audio
webcast at http://www.wsw.com/webcast/needham25/trbn/ and will be
available in the investors section of Trubion's website,
investors.trubion.com. About Trubion Trubion is a biopharmaceutical
company that is creating a pipeline of novel protein therapeutic
product candidates to treat autoimmune and inflammatory diseases
and cancer. The company's mission is to develop a variety of
first-in-class and best-in-class product candidates, customized for
optimal safety, efficacy, and convenience that it believes may
offer improved patient experiences. Trubion's current product
candidates are novel single- chain protein, or SMIP(TM),
therapeutics, and are designed using its custom drug assembly
technology. Trubion's product pipeline includes CD20-directed
candidates such as TRU-015 and SBI-087 for autoimmune and
inflammatory diseases, developed under the company's Wyeth
collaboration. Trubion's product pipeline also includes Trubion's
proprietary product candidate, TRU-016, a novel CD37-targeted
therapy for the treatment of B-cell malignancies that is currently
in Phase 1/2 clinical evaluation. In addition to Trubion's current
product candidates, the company is also developing additional
alliance and proprietary product candidates that build on its
product development experience. More information is available in
the investors section of Trubion's website: investors.trubion.com.
Contact: Jim DeNike Senior Director, Corporate Communications
Trubion Pharmaceuticals Inc. (206) 838-0500 Waggener Edstrom
Worldwide Healthcare Amy Petty Senior Account Executive (617)
576-5788 TRBN-G DATASOURCE: Trubion Pharmaceuticals Inc. CONTACT:
Jim DeNike, Senior Director, Corporate Communications of Trubion
Pharmaceuticals Inc., +1-206-838-0500, ; or Amy Petty, Senior
Account Executive of Waggener Edstrom Worldwide Healthcare,
+1-617-576-5788, , for Trubion Pharmaceuticals Inc. Web site:
http://www.trubion.com/
Copyright
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
Historical Stock Chart
From Jul 2023 to Jul 2024